Any HIV therapy that reduces the risk of an immune cell being infected by a factor of at least 100,000 is enough to keep the virus in check, researchers reported.
The finding, from a detailed mathematical model of antiviral activity, suggests why some drugs and drug combinations do better than others, according to Robert Siliciano, MD, PhD, of Johns Hopkins University in Baltimore and colleagues.
And the model also demonstrated that the complexity and cost of HIV treatment might be reduced -- and access to treatment improved -- by choosing drugs based on their ability to inhibit infection, Siliciano and colleagues reported online in Nature Medicine.
Read the full story at: http://tinyurl.com/6weyevq
Source: MedPage Today
Elevating Equitable Health Care for the LGBTQ+ Community
June 18th 2024For the third episode in our special Pride Month series, we speak with Patrick McGovern, CEO of Callen-Lorde since August of 2023 and an outspoken advocate for HIV; lesbian, gay, bisexual, transgender, queer, plus (LGBTQ+); and community health.
Listen
Updated Guidelines Allow Men Who Have Sex With Men to Join National Blood Donor Month Efforts
January 14th 2025Men who have sex with men (MSM) can now participate in National Blood Donor Month under the FDA's updated guidelines, marking a crucial step toward addressing blood shortages and promoting inclusivity.
Read More
Community Outreach Is Enabling CeSHHAR to Close HIV Care Gaps in Zimbabwe
April 6th 2021The Centre for Sexual Health and HIV/AIDS Research Zimbabwe conducts evidence-based research related to HIV and AIDS, as well as provides and implements sexual and reproductive health education and interventions among sex workers, children, and adolescents, and in the area of masculinity.
Listen